Blog

Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Photo taken from Vivek Subbiah/Twitter

Oct 5, 2023, 17:41

Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on X/Twitter:

“ANNOUNCEMENT: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6. Super thrilled to co-Chair a very important session on Tumor Agnostic and Precision Medicine with Dr. Francesco Pignatti, Head of Oncology, Haematology, Diagnostics – Safety and Efficacy Sector at European Medicines Agency (EMA).
What are the current roadblocks to histology agnostic biomarker driven approvals?
Hear directly from speakers from US FDA, EMA and from the patient perspective.”

For more information click here.
Source: Vivek Subbiah/Twitter.

Announcement cancer Diagnostics EMA ESMO European Medicines Agency Francesco Pignatti Hematology OncoDaily Oncology patient Precision Medicine US FDA Vivek Subbiah

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage